Thiabendazole

Information about Thiabendazole

Thiabendazole is a broad spectrum antihelmintic agent used predominantly in treatment of intestinal pinworm and strongyloides infection, which recently has been replaced by better tolerated agents.

Liver safety of Thiabendazole

Thiabendazole therapy has been shown to cause clinically apparent cholestatic liver injury which is rare, but can be severe.

Mechanism of action of Thiabendazole

Thiabendazole (thye" a ben' da zole) is a benzimidazole antihelmintic agent similar in structure and mechanism of action to albendazole and mebendazole. The benzimidazoles act by selective binding to beta-tubulin of parasitic worms, causing their immobilization and death.

FDA approval information for Thiabendazole

Thiabendazole was approved in the United States in 1967, but has subsequently been withdrawn because of the availability of other, better tolerated antihelmintic agents, such as ivermectin, albendazole and mebendazole. Thiabendazole is, however, still available in other countries and is used in veterinary medicine in the United States.

Dosage and administration for Thiabendazole

Its major indication is strongyloidiasis infestation. Thiabendazole was formerly available in chewable tablets of 500 mg under the trade name of Mintezol and as an oral suspensionThe typical dose in adults was 1500 mg orally daily for 1 to 3 days. The dose in children is based upon body weight.

Side effects of Thiabendazole

Thiabendazole therapy is associated with frequent minor but troublesome side effects including dizziness, nausea, diarrhea, gastrointestinal upset, headaches and hair loss.

The following are antihelmintic agents 

• Albendazole
• Ivermectin
• Mebendazole
• Nitazoxanide
• Pentamidine
• Praziquantel
• Pyrantel
• Thiabendazole

• Dailymed label info on Thiabendazole
• FDA Thiabendazole

Thiabendazole Resources
Latest articles Most recent articles Ongoing trials	Wikipedia